Frequently Asked Questions
The market is segmented based on , By Phase (Phase I, Phase II, Phase III, Phase IV), Indication (Autoimmune/Inflammation, Pain Management, Oncology, CNS Condition, Diabetes, Obesity, Cardiovascular, Others), Design (Interventional, Treatment Studies, Observational Studies, Expanded Access), End User (Hospital, Laboratories, Clinics) – Industry Trends and Forecast to 2030.
.
The Global Clinical Trials Market size was valued at USD 269.18 USD Million in 2022.
The Global Clinical Trials Market is projected to grow at a CAGR of 5.15% during the forecast period of 2023 to 2030.
The major players operating in the market include Clinipace, Laboratory Corporation of America Holdings, Eli Lilly and Company, ICON Plc., Novo Nordisk A/S, Parexel International Corporation, Pfizer , PPD , IQVIA, Sanofi, F. Hoffmann-La Roche Ltd, Alcami Corporation , Accell Clinical Research LLC, Congenix LLP, Labcorp Drug Development, Ecron Acunova, Medpace, LUMITOS AG, SIRO Clinpharm Private Limited,.
The market report covers data from the U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of the Middle East & Africa.
